✦ LIBER ✦

Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy

✍ Scribed by A. Kirschenbaum; E. Pacheco; B. J. Schuval; A. C. Levine

Book ID: 104654150
Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 306 KB
Volume: 14
Category: Article
ISSN: 0724-4983
DOI: 10.1007/bf00183115

No coin nor oath required. For personal study only.

✦ Synopsis

We attempted to correlate prostate volume reduction in response to finasteride treatment with initial prostate-specific antigen (PSA) levels and PSA density in men with symptomatic benign prostatic hyperplasia (BPH). The average reductions in prostatic volume (transrectal ultrasonography) were 27% and 34% after 6 and 12 months of finasteride therapy, respectively. Serum PSA levels decreased by 45% (6 months) and 50% (12 months). There was a positive correlation between initial serum PSA values and initial prostate volumes (r = 0.57, P < 0.001). There was no correlation, however, between the initial serum PSA or PSA-density values and prostate volume reduction. These data indicate that initial serum PSA and PSA-density values are not predictive of the response to finasteride therapy in terms of prostate size reduction.

📜 SIMILAR VOLUMES

DIFFERENTIAL RESPONSIVENESS OF PROSTATIC

DIFFERENTIAL RESPONSIVENESS OF PROSTATIC ACID PHOSPHATASE AND PROSTATE-SPECIFIC ANTIGEN mRNA TO ANDROGEN IN PROSTATE CANCER CELLS

✍ Ming-Fong Lin; Ming-Shyue Lee; Renee Garcia-Arenas; Fen-Fen Lin 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 296 KB

## Abstract Androgens regulate the expression of both human prostatic acid phosphatase (PAcP) and prostate‐specific antigen (PSA), two major prostate epithelium‐specific differentiation antigens. Due to the important role of these two enzymes as prostate epithelium differentiation markers, we inves

Diagnostic efficacy of free to total rat

Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10

✍ Shingo Yamamoto; Takuo Maruyama; Nobuyuki Kondoh; Michio Nojima; Hidekazu Takiuc 📂 Article 📅 2007 🏛 Springer Netherlands 🌐 English ⚖ 254 KB

Efficacy of androgen deprivation therapy

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer : Association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect

✍ Robert W. Ross; Wanling Xie; Meredith M. Regan; Mark Pomerantz; Mari Nakabayashi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone‐sensitive prostate cancer (HSPC) either with (M+) or without (M−) metastases. ## METHODS A cohort of prostate cancer patients was ident

Preliminary toxicity and prostate-specif

Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer•

✍ Richard G Stock; Nelson N Stone 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 118 KB

The effect of combined androgen blockade

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma : Longitudinal evaluation and response to intermittent cyclic etidronate therapy

✍ Terrence Diamond; Joanne Campbell; Carl Bryant; William Lynch 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Androgen receptor blocking agents have become an established form of therapy for men with disseminated prostate carcinoma. The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities (BMD) in men with disseminated prostate carcinoma treat